Mitsubishi UFJ Trust & Banking Corp Boosts Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 40.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,630 shares of the company’s stock after acquiring an additional 11,099 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.12% of Medpace worth $12,834,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new position in Medpace during the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp lifted its stake in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the period. Finally, True Wealth Design LLC grew its position in shares of Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Down 1.3 %

Shares of MEDP stock opened at $312.36 on Friday. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a market cap of $9.52 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The stock has a 50 day simple moving average of $335.90 and a 200-day simple moving average of $339.07.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on MEDP shares. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partners assumed coverage on Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.